Wednesday, 20 Nov 2019

You are here

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

CZP is a PEGylated, Fc‐free anti‐TNF approved for use in Crohn's disease, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.  Studies have shown little to no active placental transfer of CZP from the mother to fetus in utero.  Recent studies have also shown no or miniscule levels of CZP in the breast milk of women during lactation.

This report analyzes prospective and retrospective data on maternal CZP exposure from the UCB safety database through March 2017. Analysis was limited to prospective reports to avoid potential bias. 

Of the 1137 maternal CZP‐exposed prospective pregnancies, 528 (including 10 twin pregnancies) had 538 known outcomes: 459 live births (85.3%), 47 miscarriages (8.7%), 27 elective abortions (5.0%), and 5 stillbirths (0.9%).

A total of 8 major congenital malformations (1.7%) were seen in 459 infants.

The vast majority of these exposures were from patients with RA (n=235) or Crohn's disease (n=195) and during the first trimester (81.2%). Nearly half (44.5%) had CZP exposure during all 3 trimesters of pregnancy.

These findings are reassuring for women of childbearing age who are considering treatment with CZP.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.

Adalimumab and Pregnancy Outcomes

A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increased risk for any of the adverse outcomes examined.

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).